IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma ...Middle East

SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc....

Hence then, the article about iaso bio and innovent jointly announce the nmpa acceptance of the new drug application for equecabtagene autoleucel for the treatment of relapsed and or refractory multiple myeloma was published today ( Thursday 02/06/2022 - 03:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma )

Also on site :

• ChatGPT uninstalls surged by 295% after DoD deal
• White House Mocks Kesha Over Singer’s Outrage About “Disgusting” Use Of Song In Military Posting; She Responds: “Stop Using My Music, Perverts”
• Cursor has reportedly surpassed $2B in annualized revenue